Anna-Maria Hoffmann-Vold1,2, Håvard Fretheim1,2, Anne-Kristine Halse3, Marit Seip4, Helle Bitter5, Marianne Wallenius6,7, Torhild Garen1, Anne Salberg8, Cathrine Brunborg9, Øyvind Midtvedt1, May Brit Lund10,2, Trond M Aaløkken11, Øyvind Molberg1,2. 1. Department of Rheumatology. 2. Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 3. Department of Rheumatology, Haukeland University Hospital, Bergen, Norway. 4. Department of Rheumatology, University Hospital of North Norway, Tromso, Norway. 5. Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway. 6. Norwegian National Advisory Unit of Pregnancy and Rheumatic Diseases, Department of Rheumatology, Trondheim University Hospital, Trondheim, Norway. 7. Institute of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Norwegian University of Science and Technology, Trondheim, Norway; and. 8. Department of Rheumatology, Lillehammer Hospital, Lillehammer, Norway. 9. Oslo Centre for Biostatistics and Epidemiology, Research Support Services. 10. Department of Respiratory Medicine, and. 11. Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Abstract
Rationale: Interstitial lung disease (ILD) represents a major challenge in systemic sclerosis (SSc), but there are no precise, population-based data on its overall impact, limiting opportunities for screening and management strategies. Objectives: Evaluate impact of ILD in a unique, nationwide, population-based SSc cohort. Methods: ILD was assessed prospectively in the Norwegian SSc (Nor-SSc) cohort, including all 815 patients with SSc resident in the country from 2000 to 2012. Lung high-resolution computed tomography (HRCT) scans were available for fibrosis quantification at baseline (n = 650, 80%) and follow-up. Pulmonary function tests were assessed at baseline (n = 703, 86%) and follow-up. Vital status and standardized mortality ratios (SMRs) were estimated at study end (2018) in the 630 incident Nor-SSc cases and 15 individually matched control subjects. Cumulative survival rates were computed.Measurements and Main Results: At baseline, 50% of the subjects with SSc (n = 324) had ILD by HRCT and 46% displayed pulmonary function declines consistent with ILD progression. Mortality correlated with extent of lung fibrosis as SMR increased from 2.2 with no fibrosis to 8.0 with greater than 25% fibrosis. SMR was inversely related to baseline FVC% and increased at all FVC levels below 100%. In patients with normal-range baseline FVC (80-100%), the 5- and 10-year survival rates correlated with presence or absence of lung fibrosis, being 83% and 80%, respectively, with no fibrosis and 69% and 56%, respectively, with lung fibrosis (P = 0.03).Conclusions: The mere presence of ILD at baseline appears to affect outcome in SSc, suggesting that all patients with SSc should undergo a baseline pulmonary function test and lung HRCT screening to diagnose ILD early and tailor further management.
Rationale: Interstitial lung disease (ILD) represents a major challenge in systemic sclerosis (SSc), but there are no precise, population-based data on its overall impact, limiting opportunities for screening and management strategies. Objectives: Evaluate impact of ILD in a unique, nationwide, population-based SSc cohort. Methods: ILD was assessed prospectively in the Norwegian SSc (Nor-SSc) cohort, including all 815 patients with SSc resident in the country from 2000 to 2012. Lung high-resolution computed tomography (HRCT) scans were available for fibrosis quantification at baseline (n = 650, 80%) and follow-up. Pulmonary function tests were assessed at baseline (n = 703, 86%) and follow-up. Vital status and standardized mortality ratios (SMRs) were estimated at study end (2018) in the 630 incident Nor-SSc cases and 15 individually matched control subjects. Cumulative survival rates were computed.Measurements and Main Results: At baseline, 50% of the subjects with SSc (n = 324) had ILD by HRCT and 46% displayed pulmonary function declines consistent with ILD progression. Mortality correlated with extent of lung fibrosis as SMR increased from 2.2 with no fibrosis to 8.0 with greater than 25% fibrosis. SMR was inversely related to baseline FVC% and increased at all FVC levels below 100%. In patients with normal-range baseline FVC (80-100%), the 5- and 10-year survival rates correlated with presence or absence of lung fibrosis, being 83% and 80%, respectively, with no fibrosis and 69% and 56%, respectively, with lung fibrosis (P = 0.03).Conclusions: The mere presence of ILD at baseline appears to affect outcome in SSc, suggesting that all patients with SSc should undergo a baseline pulmonary function test and lung HRCT screening to diagnose ILD early and tailor further management.
Authors: Sydney B Montesi; Jolene H Fisher; Fernando J Martinez; Moisés Selman; Annie Pardo; Kerri A Johannson Journal: Am J Respir Crit Care Med Date: 2020-08-15 Impact factor: 21.405
Authors: Elana J Bernstein; Sara Jaafar; Shervin Assassi; Robyn T Domsic; Tracy M Frech; Jessica K Gordon; Rachel J Broderick; Faye N Hant; Monique E Hinchcliff; Ami A Shah; Victoria K Shanmugam; Virginia D Steen; Dinesh Khanna Journal: Arthritis Rheumatol Date: 2020-09-22 Impact factor: 10.995
Authors: Nina M van Leeuwen; Maaike Boonstra; Jaap A Bakker; Annette Grummels; Suzana Jordan; Sophie Liem; Oliver Distler; Anna-Maria Hoffmann-Vold; Karin Melsens; Vanessa Smith; Marie-Elise Truchetet; Hans U Scherer; René Toes; Tom W J Huizinga; Jeska K de Vries-Bouwstra Journal: Arthritis Rheumatol Date: 2021-11-02 Impact factor: 15.483
Authors: Elana J Bernstein; Shervin Assassi; Flavia V Castelino; Lorinda Chung; Chase Correia; Luke B Evnin; Tracy M Frech; Jessica K Gordon; Brian A Skaug; Faye N Hant; Laura K Hummers; Nora Sandorfi; Ami A Shah; Victoria K Shanmugam; Virginia D Steen; Dinesh Khanna Journal: ACR Open Rheumatol Date: 2022-04-23